+

WO2000017366A3 - Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament - Google Patents

Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament Download PDF

Info

Publication number
WO2000017366A3
WO2000017366A3 PCT/EP1999/006973 EP9906973W WO0017366A3 WO 2000017366 A3 WO2000017366 A3 WO 2000017366A3 EP 9906973 W EP9906973 W EP 9906973W WO 0017366 A3 WO0017366 A3 WO 0017366A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
pro
patient
treatment
need
Prior art date
Application number
PCT/EP1999/006973
Other languages
English (en)
Other versions
WO2000017366A2 (fr
Inventor
Alfred Slanetz
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Priority to AU63280/99A priority Critical patent/AU6328099A/en
Priority to JP2000574265A priority patent/JP2002526510A/ja
Priority to CA002343321A priority patent/CA2343321A1/fr
Priority to EP99950530A priority patent/EP1115871A2/fr
Publication of WO2000017366A2 publication Critical patent/WO2000017366A2/fr
Publication of WO2000017366A3 publication Critical patent/WO2000017366A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques destinées au prétraitement d'un patient nécessitant un médicament ou un promédicament, ce médicament ou ce promédicament étant surmétabolisé ou sous-métabolisé chez le patient. L'invention concerne également les utilisations de ces compositions pharmaceutiques.
PCT/EP1999/006973 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament WO2000017366A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU63280/99A AU6328099A (en) 1998-09-21 1999-09-21 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
JP2000574265A JP2002526510A (ja) 1998-09-21 1999-09-21 薬剤またはプロドラッグを必要とする患者の予備治療のための医薬組成物
CA002343321A CA2343321A1 (fr) 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament
EP99950530A EP1115871A2 (fr) 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15736698A 1998-09-21 1998-09-21
US09/157,366 1998-09-21

Publications (2)

Publication Number Publication Date
WO2000017366A2 WO2000017366A2 (fr) 2000-03-30
WO2000017366A3 true WO2000017366A3 (fr) 2000-07-13

Family

ID=22563414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006973 WO2000017366A2 (fr) 1998-09-21 1999-09-21 Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament

Country Status (5)

Country Link
EP (1) EP1115871A2 (fr)
JP (1) JP2002526510A (fr)
AU (1) AU6328099A (fr)
CA (1) CA2343321A1 (fr)
WO (1) WO2000017366A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263197B2 (en) * 2000-05-17 2006-11-09 The Board Of Regents Of The University Of Nebraska Antisense enzyme inhibitors for metabolic redirection
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
US20230100844A1 (en) * 2021-09-10 2023-03-30 ATAI Life Sciences AG Ibogaine combination treatment
WO2024223797A1 (fr) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Utilisation d'inhibiteurs de cyp3a4 pour le traitement d'infections par le virus de l'hépatite d (vhd)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035994A2 (fr) * 1996-03-27 1997-10-02 Bavarian Nordic Research Institute A/S Vecteurs retroviraux transducteurs du cytochrome p450
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
WO1998017667A1 (fr) * 1996-10-18 1998-04-30 Wayne State University 6',7'-dihydroxybergamotine, inhibiteur de cytochrome p450 ans le jus de pamplemousse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
WO1997035994A2 (fr) * 1996-03-27 1997-10-02 Bavarian Nordic Research Institute A/S Vecteurs retroviraux transducteurs du cytochrome p450
WO1998017667A1 (fr) * 1996-10-18 1998-04-30 Wayne State University 6',7'-dihydroxybergamotine, inhibiteur de cytochrome p450 ans le jus de pamplemousse

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GROVE ET AL: "the rsai polymorphism of cyp2e1 and susceptibility to alcoholic liver disease in caucasians : effect on age of presentation and dependence on alcohol dehydrogenase genotype", PHARMACOGENETICS, vol. 8, no. 4, August 1998 (1998-08-01), pages 335 - 342, XP000891939 *
INGELMAN-SUNDBERG ET AL: "ethanol-inducible cytochrome P4502e1 : genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease", ALCOHOL, vol. 10, 1993, pages 447 - 452, XP000891572 *
MEYER URS A: "Overview of enzymes of drug metabolism.", JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 1996, vol. 24, no. 5, 1996, pages 449 - 459, XP000891826, ISSN: 0090-466X *
TYNDALE ET AL: "genetically deficient cyp2d6 metabolism provides protection against oral opiate dependence", PHARMACOGENETICS, vol. 7, 1997, pages 375 - 379, XP000891834 *
UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE", CHEMICAL REVIEWS,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 90, no. 4, June 1990 (1990-06-01), pages 543 - 584, XP002916344, ISSN: 0009-2665 *

Also Published As

Publication number Publication date
CA2343321A1 (fr) 2000-03-30
JP2002526510A (ja) 2002-08-20
EP1115871A2 (fr) 2001-07-18
WO2000017366A2 (fr) 2000-03-30
AU6328099A (en) 2000-04-10

Similar Documents

Publication Publication Date Title
CA2320182A1 (fr) Compositions contenant des composes organiques
AU5402296A (en) Pharmaceutical composition for transdermic administration
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
AU2300699A (en) Amidino derivatives and drugs containing the same as the active ingredient
CA2255637A1 (fr) Conjugues d'acide cis-docosahexaenoique et de paclitaxel
BG106030A (en) Pharmaceutical composition
CA2225960A1 (fr) Compositions pharmaceutiques
AU2001290257A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001290257A2 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
AU1689999A (en) Medicinal composition for percutaneous administration
CA2368574A1 (fr) Compositions destinees a la prevention et au traitement de l'allergie de type i
CA2350659A1 (fr) Composition pharmaceutique de sensibilisateur modifiant la liberation d'insuline
IL121969A0 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives their preparation and pharmaceutical compositions containing them
CA2337667A1 (fr) Conjugues dextrane-leptine, compositions pharmaceutiques et methodes connexes
GEP20063719B (en) Prevention of Migraine Recurrence
WO2000017366A3 (fr) Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
WO1999021574A3 (fr) Amelioration d'activite morphogene
AU3192500A (en) Substituted proline derivatives and medicinal compositions containing the same
IL139863A0 (en) 3,4-diphenyl bicyclo [4.3.0] nonyl derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
WO2001022917A3 (fr) Compositions effervescentes comportant du nimesulide
AU3076600A (en) 3,7-disubstituted indole derivatives and medicinal compositions containing the same

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63280

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 63280/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999950530

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2343321

Country of ref document: CA

Ref country code: CA

Ref document number: 2343321

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 574265

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999950530

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999950530

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载